Resistance to an anti-malaria drug, artemisinin, is suspected along the Thailand-Myanmar border and in southern Vietnam, but scientists are hoping that it can be contained. Artemisinin resistance emerged on the Thailand-Cambodia border around eight years ago.

Resistance – the ability of the malaria parasite to survive drugs intended to kill it quickly – to chloroquine, an antimalarial previously widely used, forced treatment to change in the early 1970s and also originated in what is known as the Greater Mekong sub-region, which includes Cambodia, the southern provinces of China, Lao, Myanmar, Thailand and Viet Nam.

Chloroquine resistance spread to India and then to sub-Saharan Africa, which has the world’s highest burden of the disease.

Decades later, faced with another bout of resistance, officials are cautiously optimistic about preventing the spread of resistance to artemisinin.

“So far, we haven’t found any artemisinin resistance outside the Mekong region… I think we have good chances to keep it in the Mekong region,” Pascal Ringwald, coordinator of the global malaria programme for the World Health Organization (WHO), told a meeting of experts on antimalarial drug resistance in Bangkok.

He noted that the suspected cases of drug resistance along the two Thai borders appeared to be “totally independent, and it raises a concern that it could emerge anywhere.”

Roots of resistance

Resistance to artemisinin is not necessarily fatal for patients because partner drugs can boost its efficacy when it falters, but treatment may take longer and be more expensive.

Studies published earlier in April, covering more than 3,200 patients along the northwestern border of Thailand near Myanmar from 2001 to 2010, indicated a steady increase in drug resistance from 0.6 percent of surveyed patients to 20 percent after a decade.

Scientists are still searching for the exact causes of the resistance, but link it to the widespread use of monotherapies, in which only artemisinin is prescribed.

Despite an international resolution addressing the danger of monotherapies, 25 countries and 28 pharmaceutical companies continue to market them.

Monotherapies are easier and less expensive to manufacture and market than combination therapies, which pair artemisinin with other drugs (artemisinin combination therapies, or ACTs) but they speed the development of resistance to artemisinin in malaria parasites. According to WHO, the parasite is highly unlikely to become drug resistant to ACTs.

Other possible factors in resistance are parasite biology, human behaviour (like not taking the correct dosage or type of antimalaria drugs) and counterfeit drugs.

via IRIN Asia | ASIA: Containing anti-malarial drug resistance in Mekong

About the author

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Sign Up for Our Newsletter

Get notified of our weekly selection of news

You May Also Like

6 trends that will define health and wellness

COVID-19 has placed massive burdens on healthcare systems around the world. But in response to restrictions preventing in-person consultations with doctors, telemedicine – using video calls and remote monitoring – has come to the fore.

Vietnam’s Health Supplement Market: Trends, Opportunities, Market Entry

The growing demand for health supplements has resulted in increased usage of imported products as people tend to trust these brands more than domestic ones. Foreign brands tend to be positioned in the premium segment to attract mid-to-high-end consumers, while local brands generally concentrate on the mass market.

Thailand starts Monkeypox screening at international airports

According to the Department of Disease Control (DDC), travelers are now required to fill out and present a health declaration QR code card upon arriving in Thailand, allowing officials to keep track of each passenger.